The DOI matches its Crossref record; 142 of the 142 references it cites were found in a registry or an index.
Resistance to Anti-Angiogenic Therapy in Cancer—Alterations to Anti-VEGF Pathway
Open accessAbstract
Anti-angiogenic therapy is one of the promising strategies for many types of solid cancers. Bevacizumab (Avastin), a recombinant humanized monoclonal antibody of vascular endothelial growth factor (VEGF) A, was approved for the first time as an anti-angiogenic drug for the treatment of metastatic colorectal cancer (CRC) by the Food and Drug Administration (FDA) in 2004. In addition, the other VEGF pathway inhibitors including small molecule tyrosine kinase inhibitors (sunitinib, sorafenib, and pazopanib), a soluble VEGF decoy receptor (aflibercept), and a humanized monoclonal antibody of VEGF receptor 2 (VEGFR2) (ramucirumab) have been approved for cancer therapy. Although many types of VEGF pathway inhibitors can improve survival in most cancer patients, some patients have little or no beneficial effect from them. The primary or acquired resistance towards many oncological drugs, including anti-VEGF inhibitors, is a common problem in cancer treatment. This review summarizes the proposed alternative mechanisms of angiogenesis other than the VEGF pathway. These mechanisms are involved in the development of resistance to anti-VEGF therapies in cancer patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Tumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187
The biology of VEGF and its receptors
Ferrara, N., Gerber, H.-P., & LeCouter, J. (2003) · Nature Medicine · doi:10.1038/nm0603-669 · Cited by 9,591
Massagué, J. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.753 · Cited by 7,556
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
Macrophage Diversity Enhances Tumor Progression and Metastasis
Qian, B.-Z., & Pollard, J. W. (2010) · Cell · doi:10.1016/j.cell.2010.03.014 · Cited by 5,188
Vascular Endothelial Growth Factor Is a Secreted Angiogenic Mitogen
Leung, D. W., Cachianes, G., Kuang, W.-J., Goeddel, D. V., & Ferrara, N. (1989) · Science · doi:10.1126/science.2479986 · Cited by 4,986
Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1
Forsythe, J. A., Jiang, B.-H., Iyer, N. V., Agani, F., Leung, S. W., Koos, R. D., & Semenza, G. L. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.9.4604 · Cited by 3,981 · cited 7×
“HIF-1α, induced by the hypoxic microenvironment, generated during anti-angiogenic therapy stimulates β1 integrin expression, which interacts with c-MET signaling and results in an enhancement of tumor cell invasiveness [138–140].”
BackgroundInfluentialGiancotti, F. G., & Ruoslahti, E. (1999) · Science · doi:10.1126/science.285.5430.1028 · Cited by 3,869
Integrins in cancer: biological implications and therapeutic opportunities
Desgrosellier, J. S., & Cheresh, D. A. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2748 · Cited by 3,736
Kim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., & Ferrara, N. (1993) · Nature · doi:10.1038/362841a0 · Cited by 3,605
Angiopoietin-2, a Natural Antagonist for Tie2 That Disrupts in vivo Angiogenesis
Maisonpierre, P. C., Suri, C., Jones, P. F., Bartunkova, S., Wiegand, S. J., Radziejewski, C., Compton, D., McClain, J., Aldrich, T. H., Papadopoulos, N., et al. (1997) · Science · doi:10.1126/science.277.5322.55 · Cited by 3,570
Folkman, J., & Klagsbrun, M. (1987) · Science · doi:10.1126/science.2432664 · Cited by 3,491
VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche
Kaplan, R. N., Riba, R. D., Zacharoulis, S., Bramley, A. H., Vincent, L., Costa, C., MacDonald, D. D., Jin, D. K., Shido, K., Kerns, S. A., et al. (2005) · Nature · doi:10.1038/nature04186 · Cited by 3,288
Roberts, A. B., Sporn, M. B., Assoian, R. K., Smith, J. M., Roche, N. S., Wakefield, L. M., Heine, U. I., Liotta, L. A., Falanga, V, & Kehrl, J. H. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.12.4167 · Cited by 2,866
Fibroblast growth factor signalling: from development to cancer
Turner, N., & Grose, R. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2780 · Cited by 2,693
Met, metastasis, motility and more
Birchmeier, C., Birchmeier, W., Gherardi, E., & Vande Woude, G. F. (2003) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1261 · Cited by 2,602
Sternberg, C. N., Davis, I. D., Mardiak, J., Szczylik, C., Lee, E., Wagstaff, J., Barrios, C. H., Salman, P., Gladkov, O. A., Kavina, A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.9764 · Cited by 2,471
Soker, S., Takashima, S., Miao, H. Q., Neufeld, G., & Klagsbrun, M. (1998) · Cell · doi:10.1016/s0092-8674(00)81402-6 · Cited by 2,463
Wilke, H., Muro, K., Van Cutsem, E., Oh, S.-C., Bodoky, G., Shimada, Y., Hironaka, S., Sugimoto, N., Lipatov, O., Kim, T.-Y., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70420-6 · Cited by 2,438
TGFβ Signaling in Growth Control, Cancer, and Heritable Disorders
Massagué, J., Blain, S. W., & Lo, R. S. (2000) · Cell · doi:10.1016/s0092-8674(00)00121-5 · Cited by 2,385
Pàez-Ribes, M., Allen, E., Hudock, J., Takeda, T., Okuyama, H., Viñals, F., Inoue, M., Bergers, G., Hanahan, D., & Casanovas, O. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.027 · Cited by 2,339
Giantonio, B. J., Catalano, P. J., Meropol, N. J., O'Dwyer, P. J., Mitchell, E. P., Alberts, S. R., Schwartz, M. A., & Benson, A. B. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.6305 · Cited by 2,279
TGF-β Signaling in Tumor Suppression and Cancer Progression
Derynck, R., Akhurst, R. J., & Balmain, A. (2001) · Nature Genetics · doi:10.1038/ng1001-117 · Cited by 2,275
Effector Memory T Cells, Early Metastasis, and Survival in Colorectal Cancer
Pagès, F., Berger, A., Camus, M., Sanchez-Cabo, F., Costes, A., Molidor, R., Mlecnik, B., Kirilovsky, A., Nilsson, M., Damotte, D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051424 · Cited by 2,135
Vascular Permeability Factor, an Endothelial Cell Mitogen Related to PDGF
Keck, P. J., Hauser, S. D., Krivi, G., Sanzo, K., Warren, T., Feder, J., & Connolly, D. T. (1989) · Science · doi:10.1126/science.2479987 · Cited by 2,061
The Fibroblast Growth Factor signaling pathway
Ornitz, D. M., & Itoh, N. (2015) · WIREs Developmental Biology · doi:10.1002/wdev.176 · Cited by 2,050
Kerbel, R. S. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0706596 · Cited by 1,948
Batchelor, T. T., Sorensen, A. G., di Tomaso, E., Zhang, W.-T., Duda, D. G., Cohen, K. S., Kozak, K. R., Cahill, D. P., Chen, P.-J., Zhu, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.11.021 · Cited by 1,769
Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis
Ebos, J. M. L., Lee, C. R., Cruz-Munoz, W., Bjarnason, G. A., Christensen, J. G., & Kerbel, R. S. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.021 · Cited by 1,709
Carmeliet, P., Moons, L., Luttun, A., Vincenti, V., Compernolle, V., De Mol, M., Wu, Y., Bono, F., Devy, L., Beck, H., et al. (2001) · Nature Medicine · doi:10.1038/87904 · Cited by 1,672
Motzer, R. J., Michaelson, M. D., Redman, B. G., Hudes, G. R., Wilding, G., Figlin, R. A., Ginsberg, M. S., Kim, S. T., Baum, C. M., DePrimo, S. E., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.2574 · Cited by 1,634
Casanovas, O., Hicklin, D. J., Bergers, G., & Hanahan, D. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.09.005 · Cited by 1,621
Van Cutsem, E., Tabernero, J., Lakomy, R., Prenen, H., Prausová, J., Macarulla, T., Ruff, P., van Hazel, G. A., Moiseyenko, V., Ferry, D., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.8201 · Cited by 1,402
Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene
Pennacchietti, S., Michieli, P., Galluzzo, M., Mazzone, M., Giordano, S., & Comoglio, P. M. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00085-0 · Cited by 1,311
MET signalling: principles and functions in development, organ regeneration and cancer
Trusolino, L., Bertotti, A., & Comoglio, P. M. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3012 · Cited by 1,240
Signaling Vascular Morphogenesis and Maintenance
Hanahan, D. (1997) · Science · doi:10.1126/science.277.5322.48 · Cited by 1,190
Anti-Angiogenesis: New Concept for Therapy of Solid Tumors
Folkman, J. (1972) · Annals of Surgery · doi:10.1097/00000658-197203000-00014 · Cited by 1,171
Park, J. E., Chen, H. H., Winer, J., Houck, K. A., & Ferrara, N. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)47298-5 · Cited by 1,112
Escudier, B., Eisen, T., Stadler, W. M., Szczylik, C., Oudard, S., Staehler, M., Negrier, S., Chevreau, C., Desai, A. A., Rolland, F., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.5511 · Cited by 1,085
Integrins in angiogenesis and lymphangiogenesis
Avraamides, C. J., Garmy-Susini, B., & Varner, J. A. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2353 · Cited by 1,050
IL-1 is required for tumor invasiveness and angiogenesis
Voronov, E., Shouval, D. S., Krelin, Y., Cagnano, E., Benharroch, D., Iwakura, Y., Dinarello, C. A., & Apte, R. N. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0437939100 · Cited by 1,023
Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor.
Maglione, D., Guerriero, V, Viglietto, G., Delli-Bovi, P., & Persico, M. G. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.20.9267 · Cited by 999
Weber, A., Wasiliew, P., & Kracht, M. (2010) · Science Signaling · doi:10.1126/scisignal.3105cm1 · Cited by 962 · cited 8×
“PlGF stimulates growth, survival, and migration of endothelial cells, macrophages, and bone marrow progenitors, as well as tumor cells via VEGFR1 and its downstream PI3K/Akt and p38 MAPK pathways independent of VEGFA signaling [92,93].”
BackgroundInfluentialDerynck, R., Goeddel, D. V., Ullrich, A., Gutterman, J. U., Williams, R. D., Bringman, T. S., & Berger, W. H. (1987) · PubMed · Cited by 898
Environment-mediated drug resistance: A major contributor to minimal residual disease
Meads, M. B., Gatenby, R. A., & Dalton, W. S. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2714 · Cited by 892
Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells
Shojaei, F., Wu, X., Malik, A. K., Zhong, C., Baldwin, M. E., Schanz, S., Fuh, G., Gerber, H.-P., & Ferrara, N. (2007) · Nature Biotechnology · doi:10.1038/nbt1323 · Cited by 849 · cited 1×
“These observations led to the discovery that neutrophils provide the resistance mechanisms against anti-VEGF therapy [53].”
BackgroundThe Hox genes and their roles in oncogenesis
Shah, N., & Sukumar, S. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2826 · Cited by 835
Intercellular adhesion molecule-1
van de Stolpe, A., & van der Saag, P. T. (1996) · Journal of Molecular Medicine · doi:10.1007/bf00202069 · Cited by 802
Cancer classification using the Immunoscore: a worldwide task force
Galon, J., Pagès, F., Marincola, F. M., Angell, H. K., Thurin, M., Lugli, A., Zlobec, I., Berger, A., Bifulco, C., Botti, G., et al. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-205 · Cited by 791
Anti-PlGF Inhibits Growth of VEGF(R)-Inhibitor-Resistant Tumors without Affecting Healthy Vessels
Fischer, C., Jonckx, B., Mazzone, M., Zacchigna, S., Loges, S., Pattarini, L., Chorianopoulos, E., Liesenborghs, L., Koch, M., De Mol, M., et al. (2007) · Cell · doi:10.1016/j.cell.2007.08.038 · Cited by 779
Sethi, T., Rintoul, R. C., Moore, S. M., MacKinnon, A. C., Salter, D., Choo, C., Chilvers, E. R., Dransfield, I., Donnelly, S. C., Strieter, R., et al. (1999) · Nature Medicine · doi:10.1038/9511 · Cited by 739
Kowanetz, M., Wu, X., Lee, J., Tan, M., Hagenbeek, T., Qu, X., Yu, L., Ross, J., Korsisaari, N., Cao, T., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1015855107 · Cited by 663
Bv8 regulates myeloid-cell-dependent tumour angiogenesis
Shojaei, F., Wu, X., Zhong, C., Yu, L., Liang, X.-H., Yao, J., Blanchard, D., Bais, C., Peale, F. V., van Bruggen, N., et al. (2007) · Nature · doi:10.1038/nature06348 · Cited by 644
Crawford, Y., Kasman, I., Yu, L., Zhong, C., Wu, X., Modrusan, Z., Kaminker, J., & Ferrara, N. (2009) · Cancer Cell · doi:10.1016/j.ccr.2008.12.004 · Cited by 611
Clinical Implications of Circulating Angiogenic Factors in Cancer Patients
Poon, R. T.-P., Fan, S.-T., & Wong, J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.4.1207 · Cited by 587
Madri, J. A., Pratt, B. M., & Tucker, A. M. (1988) · The Journal of cell biology · doi:10.1083/jcb.106.4.1375 · Cited by 573
FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy?
Fischer, C., Mazzone, M., Jonckx, B., & Carmeliet, P. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2524 · Cited by 568
VEGF Inhibits Tumor Cell Invasion and Mesenchymal Transition through a MET/VEGFR2 Complex
Lu, K. V., Chang, J. P., Parachoniak, C. A., Pandika, M. M., Aghi, M. K., Meyronet, D., Isachenko, N., Fouse, S. D., Phillips, J. J., Cheresh, D. A., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.05.037 · Cited by 550
Targeting the PDGF signaling pathway in tumor treatment
Heldin, C.-H. (2013) · Cell Communication and Signaling · doi:10.1186/1478-811x-11-97 · Cited by 540
Willett, C. G., Duda, D. G., di Tomaso, E., Boucher, Y., Ancukiewicz, M., Sahani, D. V., Lahdenranta, J., Chung, D. C., Fischman, A. J., Lauwers, G. Y., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.1771 · Cited by 508
Signaling and Functions of Angiopoietin-1 in Vascular Protection
Brindle, N. P. J., Saharinen, P., & Alitalo, K. (2006) · Circulation Research · doi:10.1161/01.res.0000218275.54089.12 · Cited by 487
Kopetz, S., Hoff, P. M., Morris, J. S., Wolff, R. A., Eng, C., Glover, K. Y., Adinin, R., Overman, M. J., Valero, V., Wen, S., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.8252 · Cited by 485
Shojaei, F., Wu, X., Qu, X., Kowanetz, M., Yu, L., Tan, M., Meng, Y. G., & Ferrara, N. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0902280106 · Cited by 471
An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy
Chung, A. S., Wu, X., Zhuang, G., Ngu, H., Kasman, I., Zhang, J., Vernes, J.-M., Jiang, Z., Meng, Y. G., Peale, F. V., et al. (2013) · Nature Medicine · doi:10.1038/nm.3291 · Cited by 445 · cited 3×
“G-CSF and its upstream cytokine IL-17A are the main players of inflammation; thus, it is conceivable that G-CSF is abundant in tumor tissues [44].”
BackgroundSunitinib: A VEGF and PDGF receptor protein kinase and angiogenesis inhibitor
Roskoski, R. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.02.156 · Cited by 412
Rini, B. I., Michaelson, M. D., Rosenberg, J. E., Bukowski, R. M., Sosman, J. A., Stadler, W. M., Hutson, T. E., Margolin, K., Harmon, C. S., DePrimo, S. E., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.5416 · Cited by 393
Ferrari, G., Cook, B. D., Terushkin, V., Pintucci, G., & Mignatti, P. (2009) · Journal of Cellular Physiology · doi:10.1002/jcp.21706 · Cited by 340
Targeting FGFR with Dovitinib (TKI258): Preclinical and Clinical Data in Breast Cancer
André, F., Bachelot, T., Campone, M., Dalenc, F., Perez-Garcia, J. M., Hurvitz, S. A., Turner, N., Rugo, H., Smith, J. W., Deudon, S., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0190 · Cited by 311
Gotzmann, J., Mikula, M., Eger, A., Schulte-Hermann, R., Foisner, R., Beug, H., & Mikulits, W. (2004) · Mutation Research/Reviews in Mutation Research · doi:10.1016/s1383-5742(03)00033-4 · Cited by 305
Chae, Y. K., Ranganath, K., Hammerman, P. S., Vaklavas, C., Mohindra, N., Kalyan, A., Matsangou, M., Costa, R., Carneiro, B., Villaflor, V. M., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.14109 · Cited by 298
Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4
Hart, K. C., Robertson, S. C., Kanemitsu, M. Y., Meyer, A. N., Tynan, J. A., & Donoghue, D. J. (2000) · Oncogene · doi:10.1038/sj.onc.1203650 · Cited by 276
Saijo, Y., Tanaka, M., Miki, M., Usui, K., Suzuki, T., Maemondo, M., Hong, X., Tazawa, R., Kikuchi, T., Matsushima, K., et al. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.1.469 · Cited by 249
Role of Angiopoietin-2 in Adaptive Tumor Resistance to VEGF Signaling Blockade
Rigamonti, N., Kadioglu, E., Keklikoglou, I., Wyser Rmili, C., Leow, C. C., & De Palma, M. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.06.059 · Cited by 247
Rock, E. P., Goodman, V., Jiang, J. X., Mahjoob, K., Verbois, S. L., Morse, D., Dagher, R., Justice, R., & Pazdur, R. (2007) · The Oncologist · doi:10.1634/theoncologist.12-1-107 · Cited by 247
Angiopoietin signaling in the vasculature
Eklund, L., & Saharinen, P. (2013) · Experimental Cell Research · doi:10.1016/j.yexcr.2013.03.011 · Cited by 242
Piao, Y., Liang, J., Holmes, L., Zurita, A. J., Henry, V., Heymach, J. V., & de Groot, J. F. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos158 · Cited by 227
Interleukin 1 induces hypoxia-inducible factor 1 in human gingival and synovial fibroblasts
Thornton, R. D., Lane, P., Borghaei, R. C., Pease, E. A., Jaime, C. A. R. O., & Mochan, E. (2000) · Biochemical Journal · doi:10.1042/0264-6021:3500307 · Cited by 221
Overexpression of VEGF and Angiopoietin 2: A Key to High Vascularity of Hepatocellular Carcinoma?
Moon, W. S., Rhyu, K. H., Kang, M. J., Lee, D. G., Yu, H. C., Yeum, J. H., Koh, G. Y., & Tarnawski, A. S. (2003) · Modern Pathology · doi:10.1097/01.mp.0000071841.17900.69 · Cited by 210
Liu, X.-D., Hoang, A., Zhou, L., Kalra, S., Yetil, A., Sun, M., Ding, Z., Zhang, X., Bai, S., German, P., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0244 · Cited by 204
Angiopoietin‐2 expression in breast cancer correlates with lymph node invasion and short survival
Sfiligoi, C., de Luca, A., Cascone, I., Sorbello, V., Fuso, L., Ponzone, R., Biglia, N., Audero, E., Arisio, R., Bussolino, F., et al. (2003) · International Journal of Cancer · doi:10.1002/ijc.10851 · Cited by 203
Jahangiri, A., De Lay, M., Miller, L. M., Carbonell, W. S., Hu, Y.-L., Lu, K., Tom, M. W., Paquette, J., Tokuyasu, T. A., Tsao, S., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1281 · Cited by 202
Angiopoietin–Tie signalling in the cardiovascular and lymphatic systems
Eklund, L., Kangas, J., & Saharinen, P. (2017) · Clinical Science · doi:10.1042/cs20160129 · Cited by 202
Kienast, Y., Klein, C., Scheuer, W., Raemsch, R., Lorenzon, E., Bernicke, D., Herting, F., Yu, S., The, H. H., Martarello, L., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0081 · Cited by 201
LeCouter, J., Lin, R., Tejada, M., Frantz, G., Peale, F., Hillan, K. J., & Ferrara, N. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0337667100 · Cited by 201
Angiopoietin-2 Levels Are Associated with Disease Progression in Metastatic Malignant Melanoma
Helfrich, I., Edler, L., Sucker, A., Thomas, M., Christian, S., Schadendorf, D., & Augustin, H. G. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1615 · Cited by 201
Wu, Y., Hooper, A. T., Zhong, Z., Witte, L., Bohlen, P., Rafii, S., & Hicklin, D. J. (2006) · International Journal of Cancer · doi:10.1002/ijc.21865 · Cited by 192
Roland, C. L., Dineen, S. P., Lynn, K. D., Sullivan, L. A., Dellinger, M. T., Sadegh, L., Sullivan, J. P., Shames, D. S., & Brekken, R. A. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0280 · Cited by 188
Transforming growth factor-β in breast cancer: too much, too late
Barcellos-Hoff, M. H., & Akhurst, R. J. (2009) · Breast Cancer Research · doi:10.1186/bcr2224 · Cited by 187
Goede, V, Coutelle, O., Neuneier, J., Reinacher-Schick, A., Schnell, R., Koslowsky, T. C., Weihrauch, M. R., Cremer, B., Kashkar, H., Odenthal, M., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605925 · Cited by 186
Scholz, A., Harter, P. N., Cremer, S., Yalcin, B. H., Gurnik, S., Yamaji, M., Di Tacchio, M., Sommer, K., Baumgarten, P., Bähr, O., et al. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201505505 · Cited by 169
Passardi, A., Scarpi, E., Cavanna, L., Dall’Agata, M., Tassinari, D., Leo, S., Bernardini, I., Gelsomino, F., Tamberi, S., Brandes, A. A., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8901 · Cited by 167
Carbonell, W. S., DeLay, M., Jahangiri, A., Park, C. C., & Aghi, M. K. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0011 · Cited by 163
PlGF Blockade Does Not Inhibit Angiogenesis during Primary Tumor Growth
Bais, C., Wu, X., Yao, J. J., Yang, S., Crawford, Y., McCutcheon, K. M., Tan, C., Kolumam, G. A., Vernes, J.-M., Eastham‐Anderson, J., et al. (2010) · Cell · doi:10.1016/j.cell.2010.01.033 · Cited by 163
HOXB9, a gene overexpressed in breast cancer, promotes tumorigenicity and lung metastasis
Hayashida, T., Takahashi, F., Chiba, N., Brachtel, E., Takahashi, M., Godin-Heymann, N., Gross, K. W., Vivanco, M. D. M., Wijendran, V., Shioda, T., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0912710107 · Cited by 162
Allen, E., Walters, I. B., & Hanahan, D. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2847 · Cited by 157
Brown, J. L., Cao, Z. A., Pinzon-Ortiz, M. C., Kendrew, J., Reimer, C., Wen, S., Zhou, J. Q., Tabrizi, M. A., Emery, S. C., McDermott, B., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0554 · Cited by 154
Wu, Y. L., Zhong, Z., Huber, J., Bassi, R., Finnerty, B., Corcoran, E., Li, H., Navarro, E. C., Balderes, P. J., Jimenez, X., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0831 · Cited by 152
Castro, B. A., Flanigan, P. M., Jahangiri, A., Hoffman, D. B., Chen, W., Kuang, R., Lay, M. D. D., Yagnik, G., Wagner, J. R., Mascharak, S., et al. (2017) · Oncogene · doi:10.1038/onc.2017.1 · Cited by 148
Chen, Y., Li, X., Eswarakumar, V. P., Seger, R., & Lonai, P. (2000) · Oncogene · doi:10.1038/sj.onc.1203726 · Cited by 135
LaVallee, T. M., Prudovsky, I. A., McMahon, G. A., Hu, X., & Maciag, T. (1998) · The Journal of Cell Biology · doi:10.1083/jcb.141.7.1647 · Cited by 132
Martin, C., Balasubramanian, R., Dwyer, A. A., Au, M., Sidis, Y., Kaiser, U. B., Seminara, S. B., Pitteloud, N., Zhou, Q., & Crowley, W. F. (2010) · Endocrine Reviews · doi:10.1210/er.2010-0007 · Cited by 128
Prokineticin 1 Signaling and Gene Regulation in Early Human Pregnancy
Evans, J., Catalano, R. D., Morgan, K., Critchley, H., Millar, R. P., & Jabbour, H. N. (2008) · Endocrinology · doi:10.1210/en.2007-1633 · Cited by 125
DeLay, M., Jahangiri, A., Carbonell, W. S., Hu, Y., Tsao, S. W., Tom, M. W., Paquette, J., Tokuyasu, T. A., & Aghi, M. K. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2390 · Cited by 122
Phan, V. T., Wu, X., Cheng, J. H., Sheng, R. X., Chung, A. S., Zhuang, G., Tran, C., Song, Q., Kowanetz, M., Sambrone, A., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1303302110 · Cited by 119
Morris, K. T., Khan, H. Z., Ahmad, A., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2013.822 · Cited by 111
Ciombor, K. K., Berlin, J. D., & Chan, E. W. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2911 · Cited by 111
Periostin (POSTN) Regulates Tumor Resistance to Antiangiogenic Therapy in Glioma Models
Park, S. Y., Piao, Y., Jeong, K. J., Dong, J., & de Groot, J. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0427 · Cited by 102
Glioblastoma Angiogenesis and Tumor Cell Invasiveness Are Differentially Regulated by β8 Integrin
Tchaicha, J. H., Reyes, S. B., Shin, J., Hossain, M. G., Lang, F. F., & McCarty, J. H. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0991 · Cited by 99
Carbone, C., Moccia, T., Zhu, C., Paradiso, G., Budillon, A., Chiao, P. J., Abbruzzese, J. L., & Melisi, D. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1185 · Cited by 98
Induction of Bv8 Expression by Granulocyte Colony-stimulating Factor in CD11b+Gr1+ Cells
Qu, X., Zhuang, G., Yu, L., Meng, G., & Ferrara, N. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.326801 · Cited by 96
Burbridge, M. F., Bossard, C. J., Saunier, C., Fejes, I., Bruno, A., Léonce, S., Ferry, G., Violante, G. D., Bouzom, F., Cattan, V., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0075 · Cited by 96
β1 Integrin: Critical Path to Antiangiogenic Therapy Resistance and Beyond
Jahangiri, A., Aghi, M. K., & Carbonell, W. S. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1742 · Cited by 93
Botta, C., Barbieri, V., Ciliberto, D., Rossi, A., Rocco, D., Addeo, R., Staropoli, N., Pastina, P., Marvaso, G., Martellucci, I., et al. (2013) · Cancer Biology & Therapy · doi:10.4161/cbt.24425 · Cited by 92
Characterization and Regulation of Bv8 in Human Blood Cells
Zhong, C., Qu, X., Tan, M., Meng, Y. G., & Ferrara, N. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1954 · Cited by 89
Krzystek‐Korpacka, M., Diakowska, D., Kapturkiewicz, B., Bębenek, M., & Gamian, A. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.05.033 · Cited by 87
Cross-activating c-Met/β1 integrin complex drives metastasis and invasive resistance in cancer
Jahangiri, A., Nguyen, A. T., Chandra, A., Sidorov, M. K., Yagnik, G., Rick, J. W., Han, S. W., Chen, W., Flanigan, P. M., Schneidman‐Duhovny, D., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1701821114 · Cited by 84
Hainsworth, J. D., Spigel, D. R., Sosman, J. A., Burris, H. A., Farley, C., Cucullu, H., Yost, K., Hart, L. L., Sylvester, L., Waterhouse, D. M., et al. (2007) · Clinical Genitourinary Cancer · doi:10.3816/cgc.2007.n.030 · Cited by 80 · cited 1×
“Despite the success of the dual blockade of VEGFR and PDGFR by sunitinib, a combination strategy using bevacizumab (to block VEGF signaling) and imatinib (to block PDGF signaling) was not effective but was toxic during RCC treatment [89].”
BackgroundFibrocyte-like cells mediate acquired resistance to anti-angiogenic therapy with bevacizumab
Mitsuhashi, A., Goto, H., Saijo, A., Trung, V. T., Aono, Y., Ogino, H., Kuramoto, T., Tabata, S., Uehara, H., Izumi, K., et al. (2015) · Nature Communications · doi:10.1038/ncomms9792 · Cited by 79
beta1 integrin as a molecular therapeutic target
Cordes, N., & Park, C. C. (2007) · International Journal of Radiation Biology · doi:10.1080/09553000701639694 · Cited by 77
Chiron, M., Bagley, R. G., Pollard, J. R., Mankoo, P. K., Henry, C., Vincent, L., Geslin, C., Baltes, N., & Bergstrom, D. A. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0753 · Cited by 75
Antiangiogenic therapy combined with immune checkpoint blockade in renal cancer
Kuusk, T., Albiges, L. K., Escudier, B. J., Grivas, N., Haanen, J. B. A. G., Powles, T. B., & Bex, A. (2017) · Angiogenesis · doi:10.1007/s10456-017-9550-0 · Cited by 74
Integrins in Tumor Angiogenesis and Lymphangiogenesis
Foubert, P., & Varner, J. A. (2011) · Methods in molecular biology · doi:10.1007/978-1-61779-166-6_27 · Cited by 70
Norden, A. D., Schiff, D., Ahluwalia, M. S., Lesser, G. J., Nayak, L., Lee, E. Q., Rinne, M. L., Muzikansky, A., Dietrich, J., Purow, B. W., et al. (2014) · Journal of Neuro-Oncology · doi:10.1007/s11060-014-1631-y · Cited by 65
Curtis, V. F., Wang, H., Yang, P., McLendon, R. E., Li, X., Zhou, Q., & Wang, X. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054916 · Cited by 63
Placental Growth Factor Upregulation Is a Host Response to Antiangiogenic Therapy
Bagley, R. G., Ren, Y., Weber, W. D., Yao, M., Kurtzberg, L. S., Pinckney, J., Bangari, D. S., Nguyen, C., Brondyk, W. H., Kaplan, J. M., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2687 · Cited by 58
Hepatic expression of ANG2 RNA in metastatic colorectal cancer
Ogawa, M., Yamamoto, H., Nagano, H., Miyake, Y., Sugita, Y., Hata, T., Kim, B.-N., Ngan, C. Y., Damdinsuren, B., Ikenaga, M., et al. (2004) · Hepatology · doi:10.1002/hep.20048 · Cited by 53
Zhan, J., Wang, P., Niu, M., Wang, Y., Zhu, X., Guo, Y., & Zhang, H. (2014) · Histopathology · doi:10.1111/his.12585 · Cited by 52
Homeobox B9 Mediates Resistance to Anti-VEGF Therapy in Colorectal Cancer Patients
Carbone, C., Piro, G., Simionato, F., Ligorio, F., Cremolini, C., Loupakis, F., Alì, G., Rossini, D., Merz, V., Santoro, R., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3153 · Cited by 50
Tumor-Associated Fibroblasts as “Trojan Horse” Mediators of Resistance to Anti-VEGF Therapy
Francia, G., Emmenegger, U., & Kerbel, R. S. (2009) · Cancer Cell · doi:10.1016/j.ccr.2008.12.011 · Cited by 49
Lassen, U., Chinot, O. L., McBain, C. A., Mau‐Sørensen, M., Larsen, V. A., Barrié, M., Roth, P., Krieter, O., Wang, K., Habben, K., et al. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov019 · Cited by 45
Wakelee, H. A., Zvirbule, Z., de Braud, F., Kingsley, C. D., Mekhail, T. M., Lowe, T., Schütte, W., Léna, H., Lawler, W. E., Braiteh, F., et al. (2016) · Clinical Lung Cancer · doi:10.1016/j.cllc.2016.09.013 · Cited by 43
Zhou, Y., Tu, C., Zhao, Y., Liu, H., & Zhang, S. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.01.073 · Cited by 39
Chen, X., Chen, Z.-Q., Zhu, S.-L., Liu, T.-W., Wen, Y., Su, Y.-S., Xi, X.-J., Hu, Y., Lian, L., & Liu, F. (2017) · BMC Cancer · doi:10.1186/s12885-017-3215-7 · Cited by 39
Montmayeur, J., Valius, M., Vandenheede, J. R., & Kazlauskas, A. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.51.32670 · Cited by 38
Carbone, C., Tamburrino, A., Piro, G., Boschi, F., Cataldo, I., Zanotto, M., Mina, M. M., Zanini, S., Sbarbati, A., Scarpa, A., et al. (2015) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000301 · Cited by 34
Piao, Y., Henry, V. K., Tiao, N., Park, S. Y., Martínez-Ledesma, E., Dong, J. W., Balasubramaniyan, V., & de Groot, J. (2017) · Oncotarget · doi:10.18632/oncotarget.18859 · Cited by 33
Dirican, A., Varol, U., Küçükzeybek, Y., Alacacıoğlu, A., Erten, Ç., Somali, I., Can, A., Demir, L., Bayoğlu, İ. V., Akyol, M., et al. (2014) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2014.15.12.4781 · Cited by 30
Çetin, B., Ma, K., Berk, V., Ozturk, S. C., Beneklı, M., Işıkdoğan, A., Özkan, M., Çoşkun, U., & Buyukberber, S. (2012) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2012.13.3.1059 · Cited by 30
Hoshino, Y., Hayashida, T., Hirata, A., Takahashi, H., Chiba, N., Ohmura, M., Wakui, M., Jinno, H., Hasegawa, H., Maheswaran, S., et al. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-102 · Cited by 29
Semrad, T. J., Kim, E. J.-H., Tanaka, M. S., Sands, J. M., Roberts, C., Burich, R. A., Li, Y., Gandara, D. R., Lara, P. N., & Mack, P. C. (2016) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2016.12.002 · Cited by 29
Lee, C., Lee, M. E., Lee, W. S., Kim, J., Park, K.-H., Kim, T. S., Lee, K. Y., Ahn, J. B., Chung, H. C., & Rha, S. Y. (2015) · Europe PMC (PubMed Central) · Cited by 25
Cited by
VEGF in signaling and disease: beyond discovery and development
Apte, R. S., Chen, D. S., & Ferrara, N. (2019) · Cell · doi:10.1016/j.cell.2019.01.021 · Cited by 2,721
Tumor biomarkers for diagnosis, prognosis and targeted therapy
Zhou, Y., Tao, L., Qiu, J., Xu, J., Yang, X., Zhang, Y., Tian, X., Guan, X., Cen, X., & Zhao, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01823-2 · Cited by 720
Wang, S., Wang, J., Chen, Z., Luo, J., Guo, W., Sun, L., & Lin, L. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00522-z · Cited by 569
Korbecki, J., Simińska, D., Gąssowska-Dobrowolska, M., Listos, J., Gutowska, I., Chlubek, D., & Baranowska-Bosiacka, I. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910701 · Cited by 380
Effect of Stromal Cells in Tumor Microenvironment on Metastasis Initiation
Guo, S., & Deng, C.-X. (2018) · International Journal of Biological Sciences · doi:10.7150/ijbs.25720 · Cited by 315
Metadata
- Authors
- Itatani, Y., Kawada, K., Yamamoto, T., & Sakai, Y.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2018-04-18
- Volume
- 19
- Issue
- 4
- Pages
- 1232
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W2800353792
- Cited by
- 346
- References
- 142
- FWCI
- 7.38
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.